After licensing a pair of early stage nucleoside/tide reverse transcriptase inhibitors (NRTIs) and moving an in-house non-nucleoside reverse transcriptase inhibitor (NNRTI) into Phase IIb testing last month, Merck & Co. Inc. (NYSE:MRK) looks to have many of the same components for fixed-dose combination products that are being developed and/or commercialized by the market leaders in the HIV combination therapy space. Merck's newly in-licensed products include a Phase I nucleotide analog from Chimerix Inc. and a preclinical